BALTIMORE, MD--(Marketwired - Aug 27, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that Nuvilex, Inc. (
The hurdles referred to in the article are: clinical trials success, management expertise, research focus, and intellectual property. Article highlights include:
- Less than one in five firms make it to Phase III but Nuvilex appears well on its way, following the successful completion of Phase II trials for advanced, inoperable pancreatic cancer.
- CEO Dr. Robert Ryan brings a wealth of expertise in biochemistry, cell and molecular biology, human genetics, novel therapies, and cancer research to the table from a scientific perspective. One of the primary skillsets in Ryan's arsenal is his understanding and experience in guiding biotechs through the FDA regulatory process. COO Dr. Gerald Crabtree is a published expert with over 80 articles in peer-reviewed scientific journals and was a research fellow of the National Cancer Institute of Canada. Additionally, he has held roles at both large and small biotech firms from Director of Project Planning and Management for Oncology/Immunology at Bristol-Meyers Squibb and was part of the team that developed Taxol, a drug with $11B in annual sales.
- Many early stage biotech firms lack a true research focus or experience in engaging in the full R&D process leading up to a drug approval, since so few actually do make it that far. The extremes can be firms trying to be the 'jack of all trades' with a variety of platforms and applications or the opposite of delving into expensive research and development that will far exceed any payback in the form of meaningful revenue. The live-cell encapsulation platform from Nuvilex is a specific focused technology that is targeting pancreatic cancer and diabetes, large and growing markets that are still seeking viable therapeutic solutions.
- IP is the great differentiator in the small cap biotech space. Without it, these companies and stocks are almost doomed from the start. Additionally, these proprietary platforms must demonstrate significantly greater results versus the standard of care, which Nuvilex has accomplished.
With big check marks alongside these hurdles, Nuvilex has the potential to become one of biotech's major players, given its roadmap in the treatment of cancer and diabetes. As a result, the Company's stock is poised to enjoy a high valuation at a premium to other biotechs.
To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (